Preservation of Renal Function in Liver Transplant Recipients With Certican Therapy
Status:
Completed
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
The study is designed to show that everolimus initiation together with reduction and
thereafter discontinuation of calcineurin inhibitor (CNI) will improve significantly renal
function in de novo liver transplant recipients as compared to continuation of CNI-based
treatment.